Objective: We used transcranial magnetic stimulation to determine menstrual cycle related changes in cortical excitability in women with and without catamenial epilepsy and investigated whether these changes differed between ovulatory and anovulatory cohorts. peri-menstrual, C2: peri-ovulatory, and C3: luteal seizure exacerbation), non-catamenial and seizure free. Cortical excitability was assessed using motor threshold (MT) and paired pulse stimulation at short (2-15 ms) and long (100-300 ms) interstimulus intervals twice; 1. late follicular and 2. mid luteal phases of the menstrual cycle.
Introduction
Seizure clustering in relation to the menstrual cycle is a common phenomena that is found in a significant proportion (~35%) of women with epilepsy 1, 2 . Many mechanisms have been proposed to explain this association. The most established hypothesis is that it is due to neuroactive properties of sex hormones and cyclic variations in their serum levels 1, 2 . In ovulatory cycles, estrogen increases late in the follicular (pre-ovulatory) phase and then gradually declines during the luteal (pre-menstrual) phase while progesterone is low prior to ovulation and increases during the luteal phase. Evidence for this hypothesis comes from numerous clinical reports of changes in seizure patterns in relation to puberty, pregnancy and menuopause [3] [4] [5] as well as periodical hormonal fluctuations across the menstrual cycle 1, 2 . It also comes from animal data demonstrating a seizure threshold lowering effect with estrogen 6, 7 and depressed neuronal firing as well as decreased epileptiform discharges with progesterone [7] [8] [9] . This evidence is indirect, and while the anticonvulsant effects of progesterone are a common finding, there is contradictory evidence on the effects of estrogen both in clinical reports that do not link this hormone to seizure exacerbation 10 and many animal studies that do not find it to have a pro-convulsant effect [11] [12] [13] .. Furthermore, even if these competing properties were a proven feature, if seizure exacerbation in women with epilepsy was only linked to fluctuations in sex hormone levels then raised seizure risk would be predicted when the estrogen/progesterone ratio increases. This would either be right before or during ovulation when estrogen levels are at their highest or right before and during menstruation when progesterone declines. Indeed these patterns are seen in some women with catamenial epilepsy 2, 14 . However, seizure exacerbation during the entire second half (luteal phase) of the cycle when progesterone levels are expected to be high is also commonly reported 15, 16 . In some, this may be due to an inadequate luteal phase with insufficient rise in progesterone levels to be protective against seizures in these women 15, 16 . Clinical data indicating that the catamenial pattern of seizure exacerbation is more often observed in women with temporal lobe epilepsy 17 where reproductive endocrine disorders such as anovulatory cycles and oligomenorhea are also commonly present 18-20 support this proposition but it is not a universal finding 21 , nor is it applicable to all seizure types experienced by these women 19 . Furthermore, while perimenstrual and peri-ovulatory seizure clustering was found to be much more frequent in women with ovulatory than those with anovulatory cycles, luteal phase clustering was evenly distributed among both cycle types 15 . It is thus possible that epilepsy related factors influence the response of neuronal circuits to sex hormone. This interaction may be reflected as a disturbance in cortical excitability and could underlie increased seizure susceptibility in women with epilepsy.
Transcranial magnetic stimulation (TMS) is a safe and sensitive measure of both excitatory and inhibitory functions of motor cortical neurons that has a well-established role in studying cortical excitability changes in epilepsy [22] [23] [24] [25] [26] . Variations in cortical excitability were recently reported in relation to the sleep-wake cycle 27, 28 , sleep deprivation [29] [30] [31] and seizures 32, 33 in patients with epilepsy. There are also reports of variations across the menstrual cycle in normal ovulatory 34, 35 and anovulatory women 36 and in a small group with catamenial epilepsy 37 .
In the current study we used TMS in a large cohort of women with ovulatory and anovulatory cycles to determine whether there are variations in cortical excitability across the menstrual cycle in women with epilepsy. We asked whether these changes differ from healthy women without epilepsy, and if they are linked to fluctuations in sex hormone levels across the menstrual cycle. We also investigated if this difference relates to seizure patterns, such that each of the known catamenial patterns of seizure clustering would have specific cortical excitability changes which would be different compared to those observed in other women with refractory seizures and those who are seizure on medication.
Methods

I. Study populations:
The participants (non-epilepsy controls and patients) were consecutively recruited until a minimum of eight women per group completed the study. This was based on power calculations and was done to ensure evenly distributed groups. The patients were recruited through (a) Outpatient Epilepsy Clinic and (b) screening the databases of the Epilepsy Clinic and Epilepsy Surgery Program at St Vincent's Hospital in Melbourne.
These are tertiary referral centres; the first provides the management of patients with epilepsy and the latter aims for the characterization and pre-surgical evaluation of patients with refractory focal epilepsy. The diagnoses were made by at least two experienced epileptologists who were unaware of the study based on clinical history, EEG and imaging findings.
The study protocol was approved by the St Vincent's Hospital Human Research Ethics
Committee and written informed consent was obtained from each participant.
Participants were grouped according to (Table 1) :
Ovulatory/anovulatory cycles: All participants (non-epilepsy controls and patients) were divided based on their menstrual cycle profile into ovulatory and anovulatory. This was verified by asking each participant before being included to maintain menstrual diaries Page 6 of 40 for three months prior to the onset of the study. Women with regular menstrual cycles and with progesterone levels exceeding 5 ng/ml in the lutueal phase, (serum levels were measured 7±1 day before the onset of menstruation 16 ) were classified as ovulatory.
Women were assumed to have anovulatory cycles if progesterone levels did not rise above 5 ng/ml during that phase (Table 2 ).
Clinical features:
The patients were further categorized based on (Table 1) :
Syndrome:
A. "Genetic" (previously named idiopathic) generalized epilepsy syndromes including juvenile myoclonic epilepsy, juvenile absence epilepsy and generalized epilepsy with tonic-clonic seizures alone.
B. Focal epilepsy syndromes including temporal lobe and extra temporal lobe epilepsy.
Seizure frequency:
Our previous studies showed that TMS measures differ depending on whether the patients are studied at onset prior to exposure to anti-epileptic drugs (AEDs), continue to have refractory seizures or become seizure free 38 . Consequently we divided our patient groups into:
A. PATIENTS WITH REFRACTORY SEIZURES a. Peri-menstrual (C1): Seizure exacerbation on day -3 to day 3 (day 1 being the first day of menstrual bleeding).
b. Peri-ovulatory (C2): day 10 to day -13 (day -14 being mid-cycle or the day of ovulation in ovulatory cycles).
c. Luteal (C3): day -12 to day -4.
2. Non-catamenial epilepsy: Women with refractory epilepsy but with no history of seizure exacerbation in relation to the menstrual cycle.
B. SEIZURE FREE PATIENTS
Patients were included in this group if they did not experience any form of the seizures described above for at least 12 months prior to the TMS test.
Inclusion criteria:
(a) 18-40 years of age. were available for all patients and are summarized in Table 2 ).
Exclusion criteria (all participants)
(a) Fluctuation in cycle length of more than a day. (e) Any change to the AED regimen during the study or at any time in the 6 months preceding it.
II. Timing of the studies:
TMS was performed on all participants (non-epilepsy controls and patients) twice, 12-15 days apart ( Figure 1 ).
In women with ovulatory cycles, one study was in the late follicular phase (day 12 ±2, 1-2 days pre-ovulation, when estrogen is at its highest level) and the other was in the mid luteal phase (day -7 ±2, 7 days pre-menstruation, when the progesterone level is at its peak). In women with anovulatory cycles, the follicular and luteal studies were timed to coincide with approximately the same phases, the first being 1-2 days before mid-cycle and the second 5-10 days prior to the expected time of menstruation.
The timing of the two studies was calculated for each participant based on the duration of her menstrual cycles. Plasma estrogen and progesterone levels were measured at the time of each study to verify the phase of menstrual cycle.
To avoid any hypothetical "order effect", the follicular phase study was randomly performed before the luteal phase study in half the participants in each group and the order was reversed in the others.
In all groups, care was taken to perform both TMS studies for each participant between 10 am -3 pm so as to increase the repeatability of the measurements. Care was also taken to avoid clustering of any of the participants in a group to a particular time, and the studies were spread evenly over this time interval in all groups. All participants were asked to maintain regular sleep patterns with seven -nine hours of sleep the night before each study. The results were only analysed after a two day seizure free period was confirmed (based on seizure diaries) on either side of the study. If seizures were reported within this time frame, the study was repeated. No patients were excluded due to seizures.
III. Transcranial magnetic stimulation paradigm:
Both hemispheres were studied in each participant (patients and controls). During TMS, the participants sat in a comfortable, reclining chair. Surface electromyographic (EMG) recording was made from the abductor pollicis brevis muscle (APB). Stimuli were delivered to the contralateral cerebral hemisphere by applying the appropriate direction short ISIs was 100 ms and the sensitivity was set to 100 μV/division. For longer ISIs the sweep was adjusted to 500 ms and sensitivity to 2 mV/division. The MEP amplitude was measured from peak to peak.
The experimental session lasted for 60-90 minutes and the following parameters were recorded:
Motor threshold (MT):
MT was determined in all tested hemispheres while the participant was at rest, verified by continuous visual and auditory EMG feedback.
Stimulation commenced at 30% of maximum output and increased in 5% increments until the MEP was established. 1% changes in intensity were then used to measure the threshold value. Motor threshold was defined as the lowest level of stimulus intensity which produced a MEP in the target muscle of peak-to-peak amplitude > 100 μV on 50% or more of 10 trials 41 .
Intracortical inhibition and facilitation:
Cortical recovery curves were derived using paired pulse TMS. For the short ISIs of 2, 5, 10, 15 ms, the first stimulus was given at 80% of MT and the second stimulus 20% above MT. Ten stimuli at 20% above MT without a preconditioning stimulus were also given. For longer ISIs, the stimulation intensity was 20% above MT using paired stimuli in 50 ms increments at ISIs of 100 -300 ms. A minimum interval of 15 seconds was kept between the delivery of each pair of stimuli. Stimuli were given at randomly selected ISIs until a total of 10 at each ISI was achieved.
Recovery curves at short ISIs (2 -15 ms) were constructed for each hemisphere using the ratio of the mean peak to peak amplitude of the response (termed test response [TR])
at each ISI following the conditioning stimulus given below MT expressed as the percentage of the mean MEP when the test stimulus was given alone without a preconditioning stimulus (TR/MEP%).
Recovery curves at longer ISIs (100 -300 ms) were constructed for each hemisphere using the ratio of the mean peak-to-peak amplitudes of the response to the second stimulus termed the test response (TR) and the response to the first stimulus termed the conditioning response (CR) at each ISI measured as a percentage (TR/CR%).
Each participant was given a unique alpha numeric code. This was the only identifying feature on the TMS data acquired. The analysis was performed after all participants had been tested. This ensured that the investigator analysing the TMS results was blinded to clinical information during the analysis.
IV. Statistical analysis:
In non-epilepsy controls and generalized epilepsy the results were analysed according to hemisphere dominance assessed according to the Edinburgh Handedness Inventory 42 .
In focal epilepsy the results were analysed according to the ipsilateral and contralateral hemisphere (the ipsilateral hemisphere is defined here as the hemisphere with the presumed seizure focus). This was based on seizure semiology and EEG findings.
Correlation between clinical features (age, age at onset of seizures, seizure type and frequency) and AED (type and serum levels) with change in cortical excitability was performed using Pearson's correlation co-efficient as well as the chi-square test. Effect size 0.2 was considered small, 0.5 was considered medium and ≥ 0.8 was considered large 43 .
Results
There were no significant differences between the groups in the average cycle day of testing in the follicular or luteal phases. Table 1 shows the mean plasma estrogen and progesterone levels measured on the day of each TMS test in each group. Other than the expected changes in hormone levels between the two phases in each group, the only significant differences observed were lower estrogen levels during the follicular phase and lower progesterone levels during the luteal phase in all groups with anovulatory cycles compared to those with ovulatory cycles. No other significant inter-group hormone level differences were observed.
Hormonal changes
Cortical excitability measures
Inter-study variability in cortical excitability did not correlate with age, age of seizure onset or frequency or type of seizures in any of the sub-groups. It also did not correlate to the number of AEDs used or their different combinations or serum levels. .
There were no inter-hemispheric differences in any of the groups in any of the studies.
Consequently, even though the results from both hemispheres were analysed, only the results from the dominant hemisphere for non-epilepsy controls and generalized epilepsy and the ipsilateral hemisphere for focal epilepsy are presented.
There were no differences in MEP sizes to test stimuli at 120% between the groups.
Motor threshold
There were no differences in mean MT comparing the follicular and luteal values in any of the groups (Table 3) .
Intracortical inhibition and facilitation
A. Menstrual cycle variations in cortical excitability
Non-epilepsy controls
In non-epilepsy controls there was increased cortical excitability evidenced by higher Cortical excitability was higher in the luteal study in a similar fashion in both the ovulatory and anovulatory groups with no difference between them.
Non-catamenial refractory seizures
A pattern identical to that observed in patients with the C3 catamenial pattern was found, but with smaller effect sizes. 
B. Comparisons with non-epilepsy controls
Inter-group comparisons confirmed our previously reported increase in cortical excitability in patients with epilepsy compared to controls which relied on whether they were refractory or seizure free 38 Effect sizes were larger at these same ISIs when the same comparison was performed for the luteal studies (ranging from 0.5-1.7). In addition, cortical excitability was also significantly higher in both ovulatory and anovulatory generalized and focal epilepsy with refractory seizures at the 10 and 15 ms ISIs (F=4.52-8.14, p < 0.05, effect sizes ranging from 0.3 -0.7) compared to controls in the luteal studies. These changes were observed in all the refractory groups (catamenial and non-catamenial) with no differences between them.
Discussion
The current study shows that normal variations in cortical excitability during the menstrual cycle are altered in women with epilepsy regardless of clinical presentation, or type of cycle (ovulatory or anovulatory). Cortical excitability is highest in healthy, nonepileptic women during the follicular phase. In women with epilepsy, the pattern is reversed and cortical excitability is highest during the luteal phase.
Changes in cortical excitability in non-epileptic women:
Increased intracortical facilitation (10 and 15 ms ISIs) was seen during the follicular phase in normal ovulating women compared with the luteal phase. This finding replicates that published in two previous TMS studies performed in groups of healthy ovulating women across the menstrual cycle 34, 35 . Intracortical facilitation is not clearly a pure intracortical phenomenon with a suggestion of both cortical and segmental contributions 44 . Despite the complex nature of its underlying substrate, increased intracortical facilitation may be taken to imply increased glutamate mediated neuronal excitability 45 and possibly also decreased GABA A mediated inhibition 46 during the follicular phase in normal nonepileptic women. A lowering of GABA A mediated inhibition during the follicular phase is further supported by the reported reduction in intracortical inhibition at the short (< 5 ms) ISIs 47, 48 in two previous studies 34 , 35 , although we did not find this in the current study. We also found no evidence of change in long intracortical inhibition. Long intracortical inhibition is mainly thought to reflect GABA B mediated inhibition [49] [50] [51] , though this has only been pharmacologically confirmed at the 100 ms ISI. If hormonal fluctuations were an important factor underlying variations observed in cortical excitability then higher excitability during the follicular phase of ovulatory cycles could be explained by increased levels of estrogen associated with decreased levels of progesterone during the follicular phase, or it could be due to a reduction in cortical excitability in the luteal phase resulting from increased levels of progesterone. The cyclical variability could also reflect the interplay of both factors at each phase of the cycle. Hormonal fluctuations however do not explain why cortical excitability was higher during the follicular phase in women with anovulatory cycles as well. It is known that anovulatory cycles do not show the same variations in hormonal levels 16 . In addition, there is a report of increased intracortical inhibition in the luteal phase in women with anovulatory cycles compared to those with ovulatory cycles despite the high levels of progesterone in the latter group 36 . Our direct human data clearly shows a lack of difference between the women with ovulatory cycles and those with anovulatory cycles. While this contrasts with conclusions drawn from indirect evidence based on pharmacological studies mostly performed on ovariectomized animals [6] [7] [8] [9] , it is supported by others [11] [12] [13] , particularly the report that hormonal fluctuations during rats estrous cycle do not correspond at all to increased excitability measured as progression into pilocarpine-induced status epilepticus 13 . This underscores the need for more studies to clarify the physiological nature of the neuronal-hormonal interaction. It also suggests that non-hormonal factors may be involved in the cyclicity of cortical excitability changes across the menstrual cycle.
Changes in cortical excitability in women with epilepsy: Paradoxically, cortical excitability was highest (increased intracortical facilitation and decreased long intracortical inhibition) during the luteal phase of the cycle in our cohort of ovulatory and anovulatory women with both generalized and focal epilepsy. The fact that this occurs in ovulatory women as well implies that C3 patterns are not solely explained by hormonal disturbances in anovulatory cycles as suggested by clinical observations 1, 2 .
Anovulatory cycles are characterized by an abnormal absence of a substantial increase in progesterone secretion during the luteal phase despite the late follicular estrogen surge which results in a high ratio of neuroexcitatory estrogen to neuroinhibitory progesterone throughout the luteal phase 15, 16 . This disturbance does not apply to ovulatory women.
Furthermore, luteal phase seizure exacerbation cannot be fully attributed to the rapid withdrawal of the anti-seizure effects of progesterone, because cortical excitability was found to be high at a time when progesterone levels were very high (confirmed by the measurements obtained on the day of testing in our cohorts). Another intriguing finding is that increased cortical excitability in the luteal phase was not limited to women with C3 patterns. It was found in all women with epilepsy whether they suffered from catamenial epilepsy or not and even in those who were seizure free, though it was not statistically significant in the cohorts with the C1 and C2 patterns. Again there was a lack of difference between ovulatory and aovulatory women. Normal sex hormone levels were also reported despite increased cortical excitability during the luteal phase in a TMS study of ovulatory women with known catamenial epilepsy 37 . This occurred in women with all three patterns of seizure exacerbation (C1, C2 and C3), though the numbers were very small. Furthermore, we also found luteal phase hyper-excitability in a different cohort of women with new onset epilepsy who did not have a definite history of catamenial seizure clustering 52 . None of those patients were taking AEDs. All these findings show a striking reversal of the normal pattern of cortical excitability changes over the menstrual cycle in women with epilepsy which seems to occur soon after the onset of epilepsy and is present regardless of clinical presentation and use of AEDs.
The results of the present study provide novel direct human evidence that the changes in cortical excitability cannot be solely explained by hormonal fluctuations across the menstrual cycle. This is in contrast to previous observational and clinical studies on this topic, which just associated and linked periodical clustering of seizures to the hormonal changes. The findings also underscore the complexity of the effects of sex hormones on neuronal excitability, seizures and seizure induced damage. This is likely to be due to the multifaceted action of steroid hormones which include modulation of multiple genes by their up or down regulation and activation of membrane orphan G-protein coupled receptors, specific membrane hormone receptors or by direct binding to neurotransmitter receptors 53 . Alterations in GABA A (decreased short intracortical inhibition 47, 48 ) and GABA B (decreased long intracortical inhibition [49] [50] [51] ) circuits have been suggested as a mechanism for the increased cortical excitability observed in numerous TMS studies of epilepsy [22] [23] [24] [25] [26] . These changes may alter the response of intracortical circuits to all the factors involved in cyclicity of cortical excitability across the menstrual cycle (hormonal and non-hormonal) and cause neurons to interact in an atypical way to circulating sex hormones. There is evidence that the effects of estrogen can be influenced by the region or neurotransmitter system involved, the seizure type or animal model used and the specific expression of individual estrogen receptor types 54 . There are also distinct modulatory effects of estrogens on the neurotransmitter system involved in seizure genesis 54 . It is also known that progesterone metabolites function as potent positive modulators of the GABA A receptor 8, 9 , which in the setting of chronic illnesses such as epilepsy can cause changes in GABA A receptor subunit composition to compensate for sustained levels of inhibition due to periods of prolonged exposure and withdrawal 55 .
The changes in subunit composition have been shown to profoundly alter GABA A receptor structure and function 56 , and subsequently the response to hormones. While these conclusions are predominantly based on pharmacological studies on animal models and involve non-cortical structures which may not be applicable to the cortical excitability changes we observed here, they nevertheless suggest there may be 
